Using DCEs to improve equity in access to socially marketed HIV prevention products in South Africa

Fern Terris-Prestholt,

Associate Professor in the Economics of HIV, Department of Global Health and Development

With: Matthew Quaife, Catherine Macphail, Katherine Kripke

Organised Session:

Can social franchising deliver sustainable and equitable public health programmes in LMIC? Empirical evidence and methodological opportunities. 0710 14:45 HAR324 International Health Economics Congress, Boston 2017













Equity in Social Franchising

- Today:
 - Social franchising model can cover provider costs (Matovu)
 - But still primarily reaching better off (a.o. Haemmerli, Montegu)
- How can we optimise distribution across sectors?
- Could we induce users to self select across sectors by ability to pay?
- This paper:
 - Proposes using DCE to inform distribution and promotion strategy for new HIV prevention strategies to reach both the better and less well off.











Regional Communications Campaign, Archetypes

SCENE 2

We pick-up the story as Charlene makes her way into her modest home where her mother (who represents our final archetype – Florence) is in the kitchen trying to fix some food for her children. She scrapes a few ingredients together and Charlene insists that she sits down and Charlene finishes making the meal. It is at this point that she gives her mother some of the money she got from her older boyfriend. We see that her mother is grateful for the little money her daughter has given her but she is uneasy about where it comes from. We realise that Florence is not feeling well and it is at this point that Charlene enquires when she is going to go to the clinic.





(compliments of Carla Lopez, PSI/STAR)

DCEs as approach to identify market segments

- Discrete choice experiments
- Complementary approach; proof of concept
- Context: HIV prevention Trial Topical PreP for women in South Africa
 - Estimated 12% prevalence and increasing
 - Women 1.4x more like to be HIV positive than men
 - Adolescent girls 8x more likely to be HIV positive than boys of the same age
 - Products to be distributed now shelved, but for relevant for new HIV prevention product distribution, e.g. HIV self tests; Oral PreP.
- Intensive formative phase
- 1017 adult women near Johannesburg, South Africa, 2005

CHOICE Attribute	A	В
Itholakala kuphi		
E fumaneha kae	Pharmacy	
Distribution channel	Chemist/Pharmacy	Supermarket
Indlela yokuzilanda	- Filler	X
Mokgwa wa ho lata	ء	
Collection method	From a box	From a dispensing machine
Umlayezo kwisishugulu	3	(Le)
Molaetsa o mo paketeng		
Message on package	Extra Pleasure	Pregnancy Prevention
Intengo Hiwabiwa	Free,	
Price	0 Rand	10 Rand
CHOICE	1	2

DCEs as method to identify market segments

- Discrete choice experiments
- Design
 - 4 attributes, 4 levels
 - Unlabelled forced choice based on desire to acquire their preferred HIV prevention product.
 - Each participant received
 - 3 scenarios of 2 alternatives
 - across 20 blocks





Analysis

- Preferences were analysed using:
 - MNL
 - RPL
 - Latent Class model with 2 -4 classes, and
 - Latent Class RPL model.
- Market segmentation was explored based on:
 - preferred HIV prevention product (microbicide, diaphragm, condom)
 - women's liquidity:
 - o current employment chosen rather than household asset index
 - cohabitation.
- Estimated models were evaluated using BIC/n.











Table 2 Comparison of Socio Demographics Characteristics from 2005 and 2015 in the same location



Description: comparison 2005 2015

	Mean		t-test for difference		
Variable	2005	2015	(** p<0.05)		
Age	31.53	29.33	**		
Ever used contraception	72%	72%			
Employed (full or part time)	35%	39%			
Cohabiting	55%	19%	**		
Condom use at last sex	31%	43%	**		
Age at first sex	17.83	17.88			
Has children	80%	82%			
Sample size	1016	202			











Results I: Model selection

- BIC/n:
 - LC w 2 classes best fit
 - And makes sense
- Not shown:
 - MNL,
 - MNL w interactions,
 - Interaction terms in RPL models

US FROM THE AM

	Variable	3.	Latent (atent Class			4. RPL		5. LCRPL			
	Main effects	Cla	ass 1		Class2				Class 1		Class2	
n	Outlet type		Coeff.	Sig.	Coeff.	Sig.	Coeff.	Sig.	Coeff.	Sig.	Coeff.	Sig.
	Clinic		0.456	***	0.293		9.456	***	0.459	**	0.176	
	Pharmacy		0.175		0.578	***	9.568	***	- 0.313		0.870	***
	Spaza (corner shop)	-	0.146		- 0.804	***	- 11.076	***	0.311		- 1.050	***
	Supermarket	-	0.485	***	0.038		- 9.594	**	- 0.564	***	0.488	**
	Collection Mode											
	Free box or dispensing machine		0.034	**	- 0.331	**	- 1.162		0.002		0.061	
nse	a counter	-	0.239	**	- 0.145		- 5.207	***	- 0.295		- 0.231	
	In a private room		0.078		0.166		4.736	**	0.282	*	- 0.021	
	From a shelf	-	0.113		0.165		5.897	*	0.070		0.248	
	Advertising message											
ms	HIV prevention		0.336	**	- 0.069		3.674	*	0.555	**	- 0.269	*
	Pregnancy prevention		0.239	*	- 0.098		0.796		- 0.144		0.270	**
	Enhanced Pleasure	-	0.321	**	- 0.365	***	- 11.247	***	- 0.431	*	- 0.521	***
	empowerment	-	0.254		0.532	***	2.973		0.134	-	0.626	***
	Price	-	0.096	***	0.017		- 1.170	***	- 0.118	**	- 0.004	
	BIC/n		1	.311				1.414			1.552	



Results 2: Market Segments

- Class I (Housewives):
 - Unemployed, cohabiting
 - 52% of women
- Class 2:
 - Employed, not cohabiting
 - 48% of women
- Distribution preferences **not** significantly different for specific products





	4. LC (2 classes		
Variable	Coeff.	Sig.	
Constant	- 0.056		
Prefers microbicide (r.t. condoms)	- 0.178		
Prefers diaphragme (r.t. condoms)	- 0.086		
Employed	- 0.483	* * *	
Cohabiting	0.257	* *	
% of sample	52%		















- Need to undertake DCE
 - Takes time and budget
 - Based on hypothetical scenarios
 - BUT.....













- DCE, analysed with Latent class models:
 - very clear policy guidance (w.r.t. RPL):
- Could be useful for market segmentation & social marketing.
- Ultimately increase programme sustainability and equity by accounting for SES preference heterogeneity
 - -BUT Proof of concept of DCE as market segmentation tool:
 - Further evidence needed if DCE informed distribution truly more:

-Accessible and Sustainable and Equitable













Acknowledgements

- All study participants
- Interviewers and staff of Progressus Research and Development
- PATH
- The UK/DFiD Microbicide Development Programme



Support for this project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of the HealthTech V Cooperative Agreement #AID-OAA-A-11-00051 and through the U.S. Agency for International Development (USAID) in partnership with PEPFAR under the terms of Cooperative Agreement No. AID-OAA-A-15-00035. The contents are the responsibility of LSHTM and do not necessarily reflect the views of USAID or the US Government.

Thank you

Fern Terris-Prestholt <u>Fern.Terris-Prestholt@lshtm.ac.uk</u>









